Summary: Traditional anti-inflammatory approaches have often fallen short because they focus on downstream cytokines after inflammation is already established. A comprehensive new review argues a more effective strategy is to target upstream amplification mechanisms. Specifically, the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) is presented as a central amplifier of innate immune responses and a promising point of intervention for diverse inflammatory diseases.
The review brings together growing preclinical and clinical evidence clarifying TREM-1’s role. Found mainly on myeloid immune cells, TREM-1 amplifies inflammatory signalling and cross-talks with Toll‑like receptors (TLRs) to markedly increase pro-inflammatory cytokine release. When this amplification runs unchecked, it contributes to the uncontrolled inflammation underlying sepsis, to ongoing joint destruction in inflammatory arthritis, and to microglia-driven neuroinflammation that accelerates Alzheimer’s and Parkinson’s disease pathology. By intervening at this upstream node, researchers aim to prevent the downstream cascade of tissue damage.
Key Facts
- The Master Amplifier: TREM-1 does not start immune responses but acts as a potent upstream amplifier, increasing the magnitude of cytokine production during innate immune activation.
- Toll‑Like Receptor Synergy: TREM-1 amplifies inflammation through synergistic interactions with Toll‑like receptors, forming a feedback loop that can intensify tissue injury.
- Neuroinflammatory Driver: In the central nervous system, TREM-1 expressed on myeloid-lineage cells (including microglia) sustains chronic neuroinflammation and can accelerate neurodegenerative processes.
- Soluble Biomarker: The cleaved soluble form, sTREM-1, appears in body fluids during severe inflammatory states and shows promise as a prognostic biomarker for sepsis severity.
- Therapeutic Candidates: Peptide antagonists such as LR12 and LP17 have reduced tissue damage in preclinical models, and an advanced agent called nanobiotide has progressed into human clinical testing.
- Translational Challenges: Clinical development must address species differences between animal models and humans, optimize timing and dosing, and avoid broad inhibition that could impair protective baseline immunity.
Source: Far Publishing Ltd
A new review published in Current Molecular Pharmacology synthesizes evidence positioning TREM-1 as an important amplifier of innate immunity and a potential therapeutic target across acute and chronic inflammatory diseases.
Led by Eman R. Al Sawy and colleagues from Cairo University and E-JUST University, the review summarizes current understanding of TREM-1 biology, signalling networks, and its pathological roles in sepsis, inflammatory arthritis, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The authors highlight both the rationale for upstream targeting and the practical hurdles to clinical translation.
The authors note that many current therapies focus on inhibiting individual downstream cytokines, which often produces limited benefit because inflammatory networks are redundant and multifaceted. Targeting an upstream amplifier such as TREM-1 could blunt multiple downstream pathways at once, potentially arresting the runaway inflammatory response before it causes broad tissue damage.
TREM-1 is predominantly expressed on myeloid cells—macrophages, monocytes, neutrophils—and in the brain on microglia. Its activation heightens cytokine output and, through interaction with TLRs, establishes a feed-forward loop that can magnify systemic and local inflammation. The soluble form sTREM-1, resulting from receptor cleavage, is detectable in blood and other fluids and correlates with disease severity in sepsis, suggesting utility as a biomarker for prognosis and monitoring.
The review also reviews therapeutic progress: several TREM-1 inhibitors have shown efficacy in animal models, and at least one advanced inhibitor has entered early human trials. Despite promising results, the authors caution that translating these findings into safe and effective human treatments will require overcoming significant challenges.
Key translational barriers include substantial species-specific differences in TREM-1 structure and signalling between rodents and humans, which can limit the predictive value of animal studies. Another critical issue is timing: inhibiting TREM-1 too broadly or too early may undermine essential host defence mechanisms, increasing infection risk. Successful clinical strategies will likely need precise dosing, carefully defined therapeutic windows, and patient selection approaches that identify those most likely to benefit from TREM-1 modulation.
Key Questions Answered:
A: Targeting downstream cytokines is like trying to douse individual flames after a fire has spread through a house. Because the immune response uses many overlapping cytokine pathways, blocking only one pathway often leaves others active. In contrast, TREM-1 sits upstream and controls the overall magnitude of the response. Dampening TREM-1 can reduce production of multiple harmful cytokines simultaneously, offering a broader means to control complex hyper-inflammatory states.
A: Chronic, low-grade neuroinflammation is a key driver of progressive neuronal damage. TREM-1 on microglia can become persistently activated by pathological stimuli such as protein aggregates. When TREM-1 and TLR signalling interact, microglia release neurotoxic cytokines that harm synapses and neurons, accelerating neurodegeneration in conditions like Alzheimer’s and Parkinson’s disease.
A: The main challenges are species differences in TREM-1 biology, determining the correct timing and dosing to avoid compromising protective immunity, and identifying patient subgroups most likely to benefit. Addressing these issues will be essential to translate preclinical success into safe, effective therapies for humans.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this neuroinflammation and genetics research news
Author: Chris Zhou
Source: FAR Publishing Limited
Contact: Chris Zhou – FAR Publishing Limited
Image: The image is credited to Neuroscience News
Original Research: Open access. “TREM-1 receptor: A key player in inflammatory diseases” by Eman R. Al Sawy, Mona M. Saber, Noha N. Nassar, Nesrine S. El Sayed. DOI: 10.1016/j.cmp.2026.03.002
Abstract
TREM-1 receptor: A key player in inflammatory diseases
Triggering Receptor Expressed on Myeloid Cells‑1 (TREM-1) is a cell-surface receptor most abundant on myeloid-lineage cells—including macrophages, monocytes, and neutrophils—where it functions as a strong amplifier of innate immune responses. Dysregulated activation of TREM-1 has been implicated in both acute and chronic inflammatory diseases, such as sepsis, inflammatory arthritis, and neurodegenerative disorders.
Despite improvements in supportive care, targeted treatments that effectively modulate excessive inflammation are limited, especially for sepsis and neuroinflammatory conditions. Emerging preclinical and early clinical evidence supports TREM-1 as a promising therapeutic target and indicates that soluble TREM-1 may serve as a useful biomarker for disease severity and prognosis.
This review presents an updated synthesis of TREM-1 biology, signalling pathways, and pathogenic roles across disease contexts, with emphasis on recent advances in TREM-1–targeted strategies and the translational challenges that must be addressed to bring these approaches safely into clinical practice.